GSK launches three-year cost-cutting plan as new CEO targets R&D efficiency
read at Endpoints ↗Neutral
GSK announced a three-year restructuring program designed to cut costs and sharpen focus on its advanced assets.
The plan was presented by CEO Luke Miels, who has been in the role for just over six months and is using the initiative to steer the company's future.
The initiative includes a range of cost-saving actions and comes after the company recorded a £1.33 billion charge linked to a failed cough-drug trial.
GSK says the program will improve R&D efficiency and strengthen its financial position over the next three years.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Updated: GSK reveals three-year blueprint to cut costs and propel R&D”
read at Endpoints ↗90 words · retrieved Jul 28
comments(0)
5-min edit window · permanent after that